| Nov 15 |
Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges
|
| Nov 15 |
Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Celcuity GAAP EPS of -$0.70 misses by $0.05
|
| Nov 14 |
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 12 |
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
|
| Nov 7 |
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
|
| Nov 6 |
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
|
| Oct 9 |
Celcuity Inc (CELC) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses
|
| Oct 8 |
Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings
|
